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ABSTRACT
Growth and differentiation factor (GDF)-15 is a member of the transforming 
growth factor (TGF)-β family of proteins. GDF-15 levels are increased in the blood and 
cerebrospinal fluid of glioblastoma patients. Using a TCGA database interrogation, we 
demonstrate that high GDF-15 expression levels are associated with poor survival of 
glioblastoma patients. To elucidate the role of GDF-15 in glioblastoma in detail, we 
confirmed that glioma cells express GDF-15 mRNA and protein in vitro. To allow for 
a detailed functional characterization, GDF-15 expression was silenced using RNA 
interference in LNT-229 and LN-308 glioma cells. Depletion of GDF-15 had no effect 
on cell viability. In contrast, GDF-15-deficient cells displayed reduced migration 
and invasion, in the absence of changes in Smad2 or Smad1/5/8 phosphorylation. 
Conversely, exogenous GDF-15 stimulated migration and invasiveness. Large-scale 
expression profiling revealed that GDF-15 gene silencing resulted in minor changes 
in the miRNA profile whereas several genes, including members of the plasminogen 
activator/inhibitor complex, were deregulated at the mRNA level. One of the newly 
identified genes induced by GDF-15 gene silencing was the serpin peptidase inhibitor, 
clade E nexin group 1 (serpine1) which is induced by TGF-β and known to inhibit 
migration and invasiveness. However, serpine1 down-regulation alone did not mediate 
GDF-15-induced promotion of migration and invasiveness. Our findings highlight 
the complex contributions of GDF-15 to the invasive phenotype of glioma cells and 
suggest anti-GDF-15 approaches as a promising therapeutic strategy.
INTRODUCTION
Glioblastoma is an aggressive malignancy of 
the brain characterized by highly infiltrative and rapid 
growth. Despite multimodal therapy, which includes 
surgery, radiotherapy and chemotherapy, the median 
overall survival is limited to approximately 16 months 
within clinical trials [1]. Therefore, intense efforts for a 
better understanding of the biology of these tumors are 
needed to allow for the identification of novel therapeutic 
targets.
Transforming growth factor (TGF)-β is a major 
player in the promotion of glioblastoma growth and is the 
master cytokine within the TGF-β superfamily. We have 
previously shown that another member of this family, 
growth and differentiation factor (GDF)-15, also known 
as macrophage inhibitory cytokine (MIC)-1, contributes 
to the immune escape of gliomas, a hallmark of these 
tumors [2]. GDF-15 is synthetized as an inactive pro-
protein precursor that is processed by cleavage, folding and 
dimerization [3] and subsequently secreted. It may then act 
in a paracrine manner on various cells within the tumor 
microenvironment [4]. Unprocessed, secreted precursor 
molecules also bind components of the extracellular matrix, 
thereby creating latent stromal GDF-15 storages [5].
GDF-15 levels are rather low in normal tissue, 
with the exception of placenta [6] where GDF-15 
exerts immunomodulatory functions. During cancer 
development and progression, the role of GDF-15 has 
remained controversial with different findings depending 
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on the tumor entity and models investigated. GDF-15 
can promote tumor progression and plays a role in the 
development of cachexia in late stages of cancer [7, 8]. 
In the context of glioblastoma, we have characterized 
GDF-15 as a molecule that contributes to the local 
immunosuppressive environment surrounding gliomas 
pointing to a mostly paracrine mode of action [2]. 
This paracrine function is further supported by reports 
demonstrating that GDF-15 inhibits immune responses 
against hepatoma cells [9] and prevents myocardial 
damage through inhibition of immune cell infiltration 
following infarction [10]. In contrast, autocrine effects of 
GDF-15 such as the functional activity of glioma-derived 
GDF-15 on the tumor cells themselves have remained 
largely elusive. In the present study, we characterized 
the autocrine function of GDF-15 using comprehensive 
approaches including large-scale miRNA and mRNA 
expression profiling upon gene silencing, thereby aiming 
at defining the impact of GDF-15 on the malignant 
phenotype of glioma cells.
RESULTS
GDF-15 expression is associated with shorter 
survival in glioblastoma patients
We and others have previously reported that GDF-
15 levels are elevated in the blood and cerebrospinal fluid 
of glioblastoma patients [2, 11]. To assess the overall 
prognostic role of GDF-15 in glioblastoma, we performed 
a TCGA database interrogation. When the median was used 
as cut-off, glioblastoma patients with tumors displaying 
lower GDF-15 expression had longer overall survival than 
patients with tumors characterized by GDF-15 expression 
higher than the median (p = 0.017) (Fig. 1A). Moreover, 
Figure 1: Low GDF-15 expression correlates with better outcome in glioblastoma. A. TCGA data-based overall survival 
analysis of patients with tumors with high (blue) versus low (red) GDF-15 mRNA expression (p = 0.017). B. Relative GDF-15 expression 
in patient samples stratified according to the Verhaak classification. The number of classified tumors is indicated in brackets (* p < 0.05). C. 
Expression clusters defined by differential GDF-15 levels and related genes according to k-means algorithm (G1, G2, G3, G4) (* p < 0.05). 
D. Overall survival probability for patients from each expression cluster (p = 0.000026).
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the four glioblastoma subtypes defined by Verhaak and 
colleagues [12] exhibited different GDF-15 expression 
patterns, with lowest levels in the proneural subtype (Fig. 
1B). When all samples from the selected database were 
analyzed, we could define four groups (G1, G2, G3, G4), 
which can be distinguished by their expression of GDF-
15 and the associated expression of other genes (Fig. 1C). 
Within this cluster analysis, the overall survival probability 
was significantly higher for patients of group G4, which 
is characterized by the lowest GDF-15 levels (Fig. 1D), 
corroborating the hypothesis that GDF-15 contributes to the 
malignant phenotype of glioblastoma.
GDF-15 expression and gene silencing in glioma 
cell lines in vitro
We confirmed GDF-15 mRNA expression in a 
panel of 8 human long-term glioma cell (LTC) lines and 5 
glioma-initiating cell (GIC) lines in vitro. There was a trend 
for higher mRNA and protein levels in LTC than in GIC 
lines (Fig. 2A,B). The highest GDF-15 protein levels were 
found in the supernatants of LN-319 and A172 cells among 
the LTC, and of T-269 cells among the GIC (Fig. 2B). 
There was a modest correlation between GDF-15 mRNA 
expression and protein levels in the supernatant (r=0.58, p = 
Figure 2: GDF-15 is expressed in glioma cells including GIC and can be silenced by RNA interference. A. GDF-15 
mRNA expression in a panel of LTL and GIC lines was assessed by real-time PCR. B. GDF-15 levels in the supernatant of different 
glioma cell lines were determined by ELISA after cell growth for 48 h. C. LNT-229 and LN-308 cells, exposed to GDF-15-specific siRNA 
oligonucleotides or scrambed siRNA for 72 h, were assessed for GDF-15 expression by real-time PCR. D. Cell culture supernatants from 
the same cells were assessed for GDF-15 protein levels by ELISA (* p < 0.05; ** p < 0.01).
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0.04). Separate analysis of LTC alone showed no correlation 
whereas for GIC alone we noticed a strong correlation 
between mRNA and protein expression (r=0.98, p = 0.02). 
Since hypoxia is a hallmark of glioblastoma, we defined 
the impact of hypoxic conditions on GDF-15 expression 
levels in vitro. Hypoxia increased GDF-15 mRNA and 
protein levels in LN-308 cells but not significant change 
was observed in any other cell line (Suppl. Fig. 1). To allow 
for a functional characterization of GDF-15 in glioma cells, 
we silenced GDF-15 expression using RNA interference in 
LNT-229 and LN-308 cells. Expression analysis 72 h after 
exposure to specific siRNA oligonucleotides demonstrated 
a GDF-15 knock-down in the range of 70-80% as assessed 
by real-time PCR (Fig. 2C) and ELISA (Fig. 2D). Note 
that GDF-15-silenced LNT-229 cells have still much 
higher GDF-15 levels than control LN-308 cells. Efforts to 
silence GDF-15 in other LTC or GIC lines did not result in 
a sufficient knock-down for further experiments (data not 
shown).
Functional consequences of GDF-15 silencing in 
glioma cells
In order to define autocrine effects of glioma-derived 
GDF-15 in detail, we examined the effect of transient GDF-
15 gene silencing on several key features of LNT-229 and 
LN-308 glioma cells. Colony formation was not affected 
by GDF-15 depletion in either cell line (Suppl. Fig. 2A). 
Next, we analyzed the effects on cell death using annexin 
V/PI staining 48 h after GDF-15 depletion. No significant 
differences were detected upon GDF-15 silencing (Suppl. 
Fig. 2B). However, the migration and invasiveness of GDF-
15-depleted LNT-229 and LN-308 cells was significantly 
reduced (Fig. 3A). Conversely, an increase in cellular 
migration and invasion was observed when recombinant 
GDF-15 was added exogenously (Fig. 3B) which stresses 
the finding that GDF-15 may critically influence these key 
properties of glioma cells.
Impact of glioma-derived GDF-15 on the anti-
tumor activity of temozolomide and irradiation
The standard of care for glioblastoma patients 
includes alkylating chemotherapy with temozolomide 
(TMZ) and irradiation. Based on reports in other tumor 
entities, we defined the role of GDF-15 in glioma cell 
sensitivity to these treatments. Cells with transient 
GDF-15 silencing were exposed to TMZ or irradiated, 
allowed to grow and analyzed by crystal violet staining 
for clonogenic survival. GDF-15 gene silencing had no 
effect on the activity of TMZ (Suppl. Fig. 3A). Similarly, 
no significant difference was observed between the 
Figure 3: GDF-15 gene silencing reduces glioma cell migration and invasion. A. GDF-15-depleted cells or control transfectants 
(24 h) were loaded for transwell migration (left) and Matrigel invasion assays (right). Migration or invasion were assessed at 16 h and 9 
fields were counted for every single well. B. LNT-229 cells were treated with recombinant GDF-15 as indicated and migration or invasion 
experiments were performed as in (A) (* p < 0.05).
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clonogenic survival of controls and GDF-15-silenced cells 
after irradiation (Suppl. Fig. 3B). Overall, we concluded 
that GDF-15 has neither a protective nor a permissive role 
for TMZ and irradiation treatment in vitro.
Interaction of GDF-15 and TGF-β signaling 
pathways
Since GDF-15 is a member of the TGF-β 
superfamily, we assessed the impact of GDF-15 on the 
Smad pathway, which reflects the canonical down-stream 
signaling pathway for TGF-β. In contrast to TGF-β, GDF-
15 did not induce Smad2 phosphorylation in any of the cell 
lines analysed. Furthermore, and different from stimulation 
with BMP4, there was also no induction of Smad1/5/8 
phosphorylation upon GDF-15 exposure (Fig. 4A). We 
next compared the effects of GDF-15 with those of TGF-β 
on the activity of the reporter plasmid SBE4-Luc, which 
contains four copies of the Smad4 binding element. As 
expected, TGF-β
2
 stimulation resulted in marked reporter 
Figure 4: GDF-15 effects on the canonical TGF-β signaling pathway in glioma cells. A. LNT-229 or LN-308 cells were 
exposed to GDF-15 (100 ng/ml), BMP-4 (5 ng/ml) or TGF-β
2
 (10 ng/ml) as indicated for 24 h, harvested and assessed for pSmad2, 
Smad2/3, pSmad1/5/8 and Smad5 levels by immunoblot. B. LNT-229 or LN-308 cells transfected with the pGL3-SBE4-Luc reporter 
plasmid were exposed to TGF-β
2
, GDF-15, SD-208 or combinations thereof as indicated for 24 h, and analyzed for firefly/renilla luciferase 
activity. C. LNT-229 and LN-308 cells transfected with the pGL3-SBE4-Luc reporter plasmid were pre-exposed to GDF-15 for 1.5 h or not 
as indicated, subsequently treated with TGF-β
2
 for 24 h and analyzed as in (B) (* p < 0.05).
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gene induction whereas the ALK-5 inhibitor SD-208 
abrogated TGF-β
2
–induced reporter activity in LNT-229 
and LN-308 cells. No such induction of reporter activity 
was observed when GDF-15 was added in concentrations 
ranging from 0.1 to 10 ng/ml. In contrast, the reporter 
showed even a decreased activity when LN-308 cells 
were exposed to GDF-15 in a concentration-dependent 
manner (Fig. 4B). This observation raised the possibility 
of partial antagonism of TGF-β by GDF-15 at the level 
of Smad3/Smad4 activation. Indeed, as depicted in Fig. 
4C, pre-exposure of glioma cells to GDF-15 resulted in 
a reduction of the reporter activity in response to TGF-β
2
 
in LNT-229 cells. In LN-308 cells, a similar reduction of 
TGF-β-induced reporter activity was observed, however, 
only at the lower concentration of TGF-β. Altogether these 
data point to a modest inhibitory effect of GDF-15 on 
TGF-β signaling, at the level of Smad3/Smad4 activation 
in the cell lines investigated.
GDF-15 silencing affects the transcriptome of 
glioma cells
In order to gain more insights into the autocrine 
effects of glioma-derived GDF-15, we assessed the 
miRNA and mRNA expression profiles upon GDF-15 
gene silencing in LNT-229 and LN-308 cells.
As shown in Suppl. Table 1, silencing of GDF-15 
resulted in modest changes of the miRNA expression 
profile of LNT-229 and LN-308 cells. Changes in miRNA 
expression were represented almost exclusively by an 
upregulation of miRNA as determined by sequencing. 
Because of the rather small effects of GDF-15 on the 
miRNA repertoire, we next aimed at defining the effect 
of endogenous GDF-15 on the mRNA expression pattern 
in the same two glioma cell lines, using the Affymetrix 
GeneChip microarray platform. This analysis identified 
several transcripts such as members of the plasminogen 
activator/inhibitor complex, which were regulated in a 
GDF-15-dependent manner with overall similar changes 
in LNT-229 and LN-308 cells (Table 1). A bioinformatic 
analysis revealed that several of the GDF-15-controlled 
genes are involved in cell motility and metabolism. 
Further analysis of the mRNA data using the Search Tool 
for the Retrieval of Interacting Genes/Proteins (STRING) 
revealed a network of deregulated genes strongly active 
on the plasminogen activator pathway (Fig. 5A). Because 
of its central role in this pathway, we confirmed the GDF-
15-dependent regulation of serpin peptidase inhibitor, 
clade E, member 1 (serpine1), also known as plasminogen 
activator inhibitor (PAI)-1, by real-time PCR in both 
glioma cell lines (Fig. 5B). In line with these findings, 
addition of exogenous GDF-15 led to decreased serpine1 
mRNA expression levels. On the contrary, exposure to 
recombinant TGF-β induced serpine1 expression (Fig. 
5C). Finally, we confirmed the GDF-15-dependent 
regulation of serpine1 expression at the protein level using 
immunoblot and ELISA. As shown in Fig. 5D, GDF-15 
gene silencing resulted in increased serpine1 secretion 
into the cell culture supernatant confirming the GDF-15-
dependent regulation of serpine1 expression.
Since serpine1 is a known TGF-β bona fide target 
and GDF-15 a member of the TGF-β superfamily, the 
finding that GDF-15 represses the expression of serpine1 
was rather unexpected. In order to examine whether this 
effect may originate from a direct effect of GDF-15 on 
the promoter of the serpine1 gene, we used the p3TP-Lux 
reporter plasmid, which contains two of the most potent 
TGF-β responsive elements of the serpine1 promoter 
[13]. TGF-β
2
, used as a positive control, induced reporter 
activity and this effect was abrogated by SD-208 in LNT-
229 and LN-308 cells. In contrast, exogenous GDF-15 had 
no significant effect on the baseline reporter gene activity 
(Suppl. Fig. 4A) and did not interfere with TGF-β-evoked 
activity (Suppl. Fig. 4B), suggesting that GDF-15 operates 
either in a different region of the promoter or downstream 
of transcriptional activation to suppress serpine1 mRNA 
expression.
GDF-15-dependent regulation of glioma cell 
migration is not mediated through serpine1
Serpine1 is a secreted protein that inhibits the 
tissue plasminogen activator (PLAT) and the urokinase-
type plasminogen activator receptor (uPAR). uPAR is 
an important regulator of extracellular matrix (ECM) 
proteolysis, cell-ECM interactions and cell signaling 
[14]. We hypothesized that the reduced migration of 
glioma cells observed upon GDF-15 silencing could be 
a consequence of increased serpine1 expression. To this 
end, we transiently silenced GDF-15, serpine1 or both 
genes simultaneously and analyzed the migration and 
invasiveness of LNT-229 and LN-308 cells. As shown 
before, GDF-15 silencing reduced cell migration (Fig. 6A) 
and invasion (Fig. 6B) in both cell lines, whereas serpine1 
gene silencing alone had different effects: while reducing 
cell migration and invasion in LNT-229, it enhanced both 
processes in LN-308 cells which may reflect the higher 
endogenous serpine1 levels in these cells. The combined 
silencing of GDF-15 and serpine1 showed no difference 
in migration and invasion when comparing with GDF-15 
silencing alone in both cell lines, indicating that the effect 
observed in cell motility upon silencing GDF-15 is not 
mediated through serpine1.
DISCUSSION
Increased GDF-15 levels have been found in the 
blood of glioblastoma patients [2] and in the CSF where 
it correlates with poor patient outcome [11]. However, 
there are also reports suggesting that GDF-15 may act as 
a tumor suppressor [15, 16]. Here, we aimed at clarifying 
the biological role of glioma-derived GDF-15 in more 
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Figure 5: GDF-15 modulates serpine1 expression. A. STRING analysis of common genes deregulated upon GDF-15 silencing in 
LNT-229 and LN-308 cell lines (confidence view, score = 0.700, no more than 10 interactions). B. Several independent samples of GDF-
15-depleted or control transfected LNT-229 or LN-308 cells were analyzed by real-time PCR for serpine1 expression. C. The cells were 
exposed to GDF-15 or TGF-β
2
 as indicated for 24 h and subsequently examined for serpine1 expression by real-time PCR. D. Supernatants 
of cells treated as indicated in (B) for 72 h were assessed for serpine1 levels by immunoblot and GDF-15 concentration by ELISA (* p < 
0.05; ** p < 0.01).
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detail. Analysis of the gene expression dataset deposited 
in the TCGA database demonstrated that high GDF-15 
levels are associated with reduced overall survival of 
glioblastoma patients (Fig. 1A). Further analyses showed 
that GDF-15 is also differentially expressed in the context 
of the transcriptional glioblastoma subgroups described 
by Verhaak et al. [12]: proneural, neural, classical 
and mesenchymal. The reasons for the differential 
expression of GDF-15 within the 4 subgroups remain 
speculative. Highest GDF-15 levels were found in the 
mesenchymal subgroup which may respond best to various 
immunotherapeutic strategies that are currently under 
development [17, 18]. Thus, targeting GDF-15 and thereby 
abrogating its immunosuppressive properties may be a 
Table 1: Differential gene expression upon GDF-15 gene silencing in glioma cells 
Symbol Name LNT-229 LN-308
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1
3.00 2.85
GDF15 growth and differentiation factor 15 2.58 5.15
RGS4 regulator of G-protein signaling 4 2.54 1.54
ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 2.16 1.42
CAPN3 calpain 3, (p94) 2.02 1.21
MICAL2 microtubule associated monoxygenase, calponin and LIM domain 
containing 2
1.72 1.29
PLAT plasminogen activator, tissue 1.70 1.40
TNC tenascin C 1.65 1.33
PLAUR plasminogen activator, urokinase receptor 1.61 1.33
L1CAM L1 cell adhesion molecule 1.58 1.22
PTMA prothymosin, alpha 1.66 1.55
JUN jun proto-oncogene 1.48 1.41
SLC2A10 solute carrier family 2 (facilitated glucose transporter), member 10 1.45 1.47
CD59 CD59 molecule, complement regulatory protein 1.45 1.43
ACADVL acyl-CoA dehydrogenase, very long chain 1.43 1.37
SLC25A46 solute carrier family 25, member 46 1.41 1.24
DDR1 discoidin domain receptor tyrosine kinase 1 1.40 1.21
TPST1 tyrosylprotein sulfotransferase 1 1.39 1.26
PON2 paraoxonase 2 1.36 1.29
LEPREL2 leprecan-like 2 1.36 1.41
GNA11 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) 1.34 1.42
KYNU kynureninase (L-kynurenine hydrolase) 1.33 1.06
HIPK2 homeodomain interacting protein kinase 2 1.33 1.14
PLIN3 perilipin 3 1.31 1.15
TMPO thymopoietin 1.31 1.23
UBE4B ubiquitination factor E4B (UFD2 homolog, yeast) 1.31 1.08
ANXA1 annexin A1 1.30 1.11
MLLT11 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 11
1.29 1.05
The most deregulated genes for both cell lines are shown. Bold values imply up-regulation, with fold change values 
expressed as x=(GDF-15 siRNA/scrambled siRNA). Grey values represents down-regulation and fold change values are 
expressed as x=(scrambled siRNA/ GDF-15 siRNA). Significant genes were included for a p value cut-off of 0.01 for non-
paired T test
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potentially beneficial therapeutic strategy in this molecular 
subgroup. When all dataset samples were grouped in 4 
clusters, regardless of their subtype classification but 
according to their GDF-15 expression levels, we noticed 
that the group of patients whose tumors had the lowest 
GDF-15 expression levels had prolonged survival (Fig. 
1D). Although requiring confirmation in another dataset 
with control for other prognostic factors, these findings 
corroborate previous reports indicating that GDF-15 
contributes to the malignant phenotype of glioblastoma 
[2, 11, 19]. Hypoxia resulted in increased GDF-15 levels 
in LN-308 cells which supports previous findings [19]. 
However, no effect of hypoxic conditions was observed 
in various other glioma cell lines suggesting that hypoxia 
might not be a major driver of GDF-15 expression.
GDF-15 gene silencing using RNA interference 
did not reduce glioma cell viability (Suppl. Fig. 2). Of 
note, we used only a transient silencing of GDF-15 and it 
remains unclear whether a stable GDF-15 gene silencing 
would have resulted in different effects on clonogenic 
survival. Most importantly, two key characteristics of 
glioma cells, migration and invasion, were impaired 
upon GDF-15 depletion. In line with these findings, the 
addition of recombinant GDF-15 enhanced cell migration 
and invasion (Fig.s 3A and 3B) indicating that autocrine 
GDF-15 signaling plays an important functional role 
in glioma cells. The contribution of GDF-15 to the 
invasiveness of cancer cells has also been described in the 
context of gastric cancer cells [20]. Furthermore, it was 
reported that GDF-15 protects prostate cancer [21] and 
colon cancer [22, 23] cells from the deleterious effects of 
chemotherapeutic agents. In contrast to these findings, we 
did not observe any change in the susceptibility of glioma 
cells to the alkylating agent, TMZ, or to irradiation (Suppl. 
Fig. 3).
Since a receptor for GDF-15 has not yet been 
characterized, there is no consensus on the signaling 
pathway for this molecule under physiological and 
pathological conditions [4]. Because GDF-15 belongs to 
the TGF-β superfamily, we aimed at disclosing whether 
Figure 6: GDF-15 and serpine1 act independently on glioma cell migration and invasion. LNT-229 or LN-308 cells were 
transiently transfected with control siRNA or siRNA molecules targeting GDF-15 or serpine1 as indicated. After 48 h, the cells were used 
for transwell migration A. or matrigel invasion B. experiments. The assays were stopped after 16 h. Cells present in 9 fields were counted 
for every single well, 3 wells for each condition (* p < 0.05; ** p < 0.01).
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any of the canonical signaling pathways described for this 
family, which are represented by the activation of Smad2/3 
or Smad1/5/8 [24, 25], are affected by GDF-15. Exposure 
of LNT-229 or LN-308 cells to recombinant GDF-15 did 
not trigger Smad2 or Smad1/5/8 phosphorylation, a finding 
that is in line with previous reports in gastric cancer cells 
[20]. Furthermore, pSmad3/Smad4 complex activation 
was not observed upon GDF-15 stimulation as assessed 
using the SBE4 gene reporter [13]. On the contrary, we 
noticed a reduction of the basal reporter activity in LN-308 
cells when GDF-15 was applied (Fig. 4B). Competition 
experiments demonstrated a reduced reporter activity in 
response to TGF-β in the presence of GDF-15 in LNT-
229, and the same at low concentrations of TGF-β in LN-
308 cells. Since LNT-229 cells are characterized by low 
endogenous TGF-β
2
 activity, we concluded that GDF-15-
mediated interference with canonical TGF-β signaling may 
only occur when this pathway is not strongly activated.
To increase the understanding of autocrine GDF-15 
effects in glioma cells, we analyzed miRNA and mRNA 
expression profiles by sequencing and array technology, 
respectively. Although GDF-15 had different effects on 
the miRNA expression in the 2 cell lines investigated 
(Suppl. Table 1 ), there were overall only minor changes 
indicating that the observed functional consequences 
of GDF-15 gene silencing are probably not mediated at 
the level of miRNA function. More pronounced changes 
were noticed at the mRNA level upon GDF-15 depletion. 
When analyzing the dataset using the STRING algorithm 
for gene interaction visualization, we detected that 
several genes were clustered around the plasminogen 
activation pathway: plasminogen activator urokinase 
type (PLAU), PLAU receptor (PLAUR), PLAT, tenascin 
(TNC), serpine1, as well as genes directly involved in cell 
motility such as members of the mitogen activated protein 
kinase (MAPK) pathway. Unexpectedly, the expression 
of serpine1, the most deregulated gene, is inhibited by 
GDF-15 in contrast to the effect of TGF-β, a well-known 
inducer of serpine1 expression [26]. GDF-15-dependent 
regulation of serpine1 expression was confirmed in 
independent experiments at the transcriptional and protein 
levels. We elaborated on this in more detail and used 
the p3TP-Lux reporter plasmid [13] which contains the 
most potent TGF-β responsive element of the human 
serpine1 promoter and has been widely used as a TGF-β 
reporter system. While exposure to TGF-β resulted in 
increased reporter activity, no response was recorded 
upon GDF-15 administration. Furthermore, GDF-15 did 
not abrogate TGF-β-mediated induction of reporter gene 
activity suggesting that the inhibitory effect of GDF-15 
on serpine1 mRNA expression might be due to repression 
of the serpine1 gene in other regions of the promoter not 
being part of the reporter plasmid or mediated through 
other posttranscriptional mechanisms that cause mRNA 
instability.
Upon secretion to the extracellular medium, 
serpine1 interacts with soluble PLAT and the extracellular 
domain of uPAR, inhibiting their serin-protease activity 
and ultimately resulting, among other effects, in reduced 
activity of matrix metalloproteinases (MMP) [14, 27]. 
MMP can degrade ECM components and release growth 
factors retained within the ECM such as TGF-β [28, 29]. 
Furthermore, uPAR is an important regulator of ECM 
proteolysis, cell-ECM interactions and cell signaling 
involved in actin cytoskeleton remodeling [14, 30, 31]. 
Accordingly, we hypothesized that GDF-15-mediated 
down-regulation of serpine1 levels may enhance the 
activity of this cascade resulting in increased tumor cell 
motility. However, when GDF-15 and serpine1 were 
silenced, either alone or in combination, we did not 
recognize a clear link between GDF-15, serpine1 and the 
observed phenotype (Fig. 6). Of note, silencing of serpine1 
alone had different effects on the invasion and migration 
of LNT-229 and LN-308 glioma cells. This might be 
explained by the different constitutive expression levels 
and functional relevance of serpine1 in the two cell lines.
In conclusion, we delineate GDF-15 as a molecule 
that promotes migration and invasion of glioma cells 
suggesting a relevant contribution to the malignant 
phenotype of these tumors. Furthermore, GDF-15 has been 
described as an important immunosuppressive cytokine in 
the context of gliomas and other pathological conditions 
[2, 9, 10, 32]]. In light of the various immunotherapeutic 
approaches which are currently being investigated 
in glioblastoma patients, the autocrine and paracrine 
functions of GDF-15 may make it an attractive target for 
novel therapeutic strategies.
MATERIALS AND METHODS
Cells and reagents
The human LTC lines A172, U87MG and T98G 
were purchased from the American Type Culture 
Collection. LN-18, LNT-229, LN-308, LN-319 and LN-
428 cells were kindly provided by Dr. N. de Tribolet 
(Lausanne, Switzerland). LTC were maintained in 
Dulbecco’s modified eagle medium (DMEM, Invitrogen, 
Life Technologies, Carlsbad, CA), containing 10% fetal 
calf serum (FCS) (VWR Lonza, Leighton Buzzard, UK) 
and supplemented with 2 mM glutamine (Invitrogen, 
Life Technologies), in a 5% CO
2
 incubator at 37° C. The 
GIC lines S-24, T-269, T-325, ZH-161 and ZH-305 were 
generated and cultured as described [33–35]. GIC were 
maintained as sphere cultures in Neurobasal A medium 
(Invitrogen, Life Technologies) supplemented with EGF 
(10 ng/ml), FGF (10 ng/ml) (Peprotech, Rocky Hill, 
NJ), heparin (31.5 U/ml) (Sigma Aldrich, St. Louis, 
MO), 1% Glutamax (Invitrogen, Life Technologies) and 
2% B27 (Invitrogen, Life Technologies). Adherent cells 
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were detached with TrypLE Express (Invitrogen, Life 
Technologies). For experiments under hypoxic conditions, 
the cells were cultured in a hypoxia chamber adjusted to 
5% CO
2
 and 1% O
2
 at 37°C.
Recombinant human TGF-β
2
 (rh-TGF-β
2
) and 
BMP-4 (rh-BMP4) were purchased from R&D Systems 
(Minneapolis, MN), recombinant human GDF-15 (rh-
GDF-15) from Peprotech. The following antibodies 
were used for immunoblot experiments: rabbit anti-
human phospho-Smad2 (Ser465/467) (clone 138D4, 
Cell Signaling Technology, Danvers, MA), rabbit anti-
human Smad2 (clone 86F7, Cell Signaling Technology), 
rabbit anti-human phospho-Smad1(ser463/465)/Smad-
5(ser463/465)/Smad8(Ser426/428, Cell Signaling 
Technology), rabbit anti-human Smad5 antibody 
(Cell Signaling Technology), goat anti-human actin 
(Santa Cruz Biotechnology, Dallas, TX), goat anti-
human serpine1 (Acris Antibodies, Inc, San Diego, 
CA). The TGF-β receptor I kinase inhibitor SD-208 
was kindly provided by Scios Inc (Fremont, CA). 
Temozolomide (TMZ) was provided by Schering-Plough 
(Kenilworth, NJ).
Gene expression and Kaplan-Meier analysis of 
survival probability using The Cancer Genome 
Atlas (TCGA) dataset
Overall survival analysis within the TCGA database 
(http://cancergenome.nih.gov), for glioblastoma 540 
- MAS5.0 - u133a dataset (n = 540) was performed 
using the Kaplan-Meier analysis module of the R2: 
microarray analysis and visualization platform (http://
r2.amc.nl). The scan cut-off mode based on median GDF-
15 expression was selected without specifying a track 
subset. Analysis of GDF-15 expression by glioblastoma 
subtype [12] was done using 85 samples classified into 
these groups within the subtype track mode and z-score 
transformation. Generation of GDF-15 expression clusters 
across the whole 540 — MAS5.0 dataset was performed 
with k-means algorithm and 2Log transformation of gene 
expression. Kaplan-Meier overall survival curves were 
plotted for the generated clusters.
GDF-15 enzyme-linked immunosorbent assay 
(ELISA)
1.5 × 106 glioma cells were seeded in a 5 cm dish 
or a T25 flask in complete medium and allowed to attach 
or form spheres for 24 h. Medium was subsequently 
changed to FCS- or B27-free medium. Supernatants were 
harvested and stored at -80 °C until further assessment by 
ELISA (R&D Systems). Total protein concentration for 
normalization was determined using the Pierce™ BCA 
Protein Assay Kit (Thermo Scientific, Lafayette, CO).
RNA interference-mediated gene silencing
Glioma cells were seeded at proper density for 
each cell line on a six-well plate or 6 cm tissue culture 
dishes (TPP, Trasadingen, Switzerland), allowed to attach 
overnight and transfected with ON-TARGET plus human 
GDF-15 siRNA SMARTpool or ON-TARGET plus non-
targeting pool (Dharmacon/Thermo Scientific, Lafayette, 
CO). The transfection reagent used was Metafectene® 
Pro (Biontex, Switzerland). Nine hours after transfection, 
the medium was changed to FCS-free medium. Cells and 
supernatants were harvested at 24, 48 or 72 h.
Real-time polymerase chain reaction
Total RNA was prepared using the NucleoSpin® 
kit (Macherey Nagel GmbH, Düren, Germany). 
Complementary DNA was prepared using the 
iScript® kit (BioRad, Hercules, CA). For real-time 
PCR, gene expression was measured in an Applied 
Biosystems 7300 Real-Time PCR System using the 
ABI Prism 7000 Sequence Detection System (Applied 
Biosystems, Carlsbad, CA) with SYBR Green ROX 
Mix (Thermo Scientific) and primers (Microsynth 
AG, Balgach, Switzerland) at a final concentration 
of 0.4 μM. GAPDH and GDF-15 primers have been 
described [2, 36]. Other primer sequences were: 
serpine1 fwd: 5′-GCTTACAGGAGCTTTTGTGT-3′, 
rev: 5′-ACTCTGAGATGAAAGGGTGTTT-3′, HPRT 
fwd: 5′- TGAGGATTTGGAAAGGGTGT-3′, rev: 
5′-GAGCACACAGAGGGCTACAA-3′. The conditions 
were 40 cycles at 95°C/15 s and 60°C/1 min. Standard 
curves were generated for each gene and the amplification 
was 90–100% efficient. Relative quantification of gene 
expression was determined by comparison of threshold 
values. Results were normalized to HPRT and calculated 
with the ΔCT method for relative quantification [37].
Clonogenic survival assay
Clonogenic assays were performed by seeding 500 
cells per well in 96-well plates. After overnight attachment, 
the cells were exposed to different agents as indicated 
for 24 h, in FCS-free medium in case of TMZ, followed 
by observation for 7–14 days in complete medium. Cell 
density was assessed by crystal violet staining.
Flow cytometry
For cell death analysis, cells were detached with 
AccutaseTM (PAA, Pasching, Austria) and 5 × 105 cells 
were used per staining. Cells re-suspended in Annexin 
buffer [10 mM HEPES, 140 nM NaCl, 2.5 mM CaCl
2
, 
pH= 7.4] were stained with Annexin-V-FITC (BD 
Biosciences) and propidium iodide (PI) (Sigma-Aldrich) 
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for 15 min at room temperature in the dark and analyzed 
by flow cytometry.
Migration and invasion
Cells with transient GDF-15 gene silencing, 
control transfectants or cells pre-treated with 100 ng/
ml rh-GDF-15 for 24 h were detached, washed and re-
suspended in serum-free medium alone or supplemented 
with rh-GDF-15. A cell suspension containing 50000 cells 
was added to the upper well of transwell migration inserts 
(pore size: 8 μm, BD Biosciences) or to BD BioCoatTM 
MatrigelTM invasion chambers (pore size: 8 μm, BD 
Biosciences). In the lower well, 700 μl of complete 
medium were used as chemo-attractant. The cells were 
kept for 16 h at 37 °C and 5% CO
2
, followed by fixation 
in cold methanol for 10 min and staining with Mayer’s 
alum haematoxylin for 1 h. Inserts were mounted in glass 
slides and 9 fields per sample were counted, 3 replicates 
of each treatment.
Immunoblot analysis
The cells were lysed in radioimmunoprecipitation 
assay (RIPA) buffer [10 mM Tris pH 8.0, 150 mM 
NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS] 
supplemented with 1% complete protease inhibitor mix 
(Roche Diagnostics, Basel, Switzerland) and phosphatase 
inhibitor cocktails 1 and 2 (Sigma-Aldrich). Serum-free 
conditioned media were concentrated using Centriplus 
Centrifugal Filter Device YM-3 (3000 Da cut-off; 
Millipore, Billerica HQ, MA). Protein concentration 
was measured with the Bradford protein assay reagent 
(Bio-Rad) using bovine serum albumin as a standard. 
Samples were mixed with Laemmli buffer containing 10% 
β-mercaptoethanol (BioRad). Twenty μg of protein were 
loaded per lane, in a 12% poly acrylamide gel. Protein 
transfer was performed using nitrocellulose 45 μm pore 
size (BioRad). Equal protein loading was ascertained 
by actin detection. Visualization of protein bands was 
accomplished using horseradish peroxidase–coupled 
secondary antibodies (Sigma-Aldrich) diluted 1:5000 with 
enhanced chemoluminescence (ECL, Thermo Scientific).
Luciferase-gene reporter assay
The pGL3-SBE4-Luc reporter plasmid was kindly 
provided by Dr. Bert Vogelstein (Baltimore, MD). 
This reporter has 4 copies of the Smad4 binding site of 
Vestigial (Vg) Drosophila gene palindrome sequences 
on the promoter of firefly luciferase, cloned in the pBV-
Luc vector [38]. The pGL2-3TP-Luc construct contains 
a synthetic promoter composed of a TGF-β-responsive 
fragment of the promoter of the human plasminogen 
activator inhibitor-1 (PAI-1 or serpine1) gene inserted 
downstream of three phorbol ester-responsive elements 
[13], kindly provided by J. Massague (New York, NY). 
Dual luciferase firefly/renilla assays were performed 
with co-transfection of 150 ng of the respective reporter 
construct and 20 ng of pRL-CMV VECTOR (Promega, 
Madison, WI). Luciferase activity was normalized to 
constitutive renilla luciferase activity (pRL-CMV).
Microarray-based gene expression profiling
GDF-15-dependent gene regulation was examined 
in LNT-229 and LN-308 glioma cells. To this end, the 
cells were transfected with GDF-15-specific siRNA 
oligonucleotides or scrambled control. Total RNA was 
extracted with the RNeasy kit (Qiagen, Hilden, Germany) 
72 h after transfection. Gene expression profiling was 
performed using hybridization of Affymetrix Gene Chip 
HG-U133 Plus 2.0 arrays (Affymetrix, Santa Clara, 
CA). High quality of the extracted RNA (RNA integrity 
number > 9.0) was assured by using the Agilent 2100 
Bioanalyzer (Agilent Technologies, Böblingen, Germany). 
The Affymetrix 3′IVT express kit was used for sample 
preparation and labeling starting with 100 ng total RNA. 
After fragmentation, labeled cRNA was hybridized to the 
microarrays for 16 h at 42°C, stained with strepatavidin/
phycoerythrin conjugate, and scanned. Data analyses on 
Affymetrix CEL files were conducted with the GeneSpring 
GX software (Vers. 12.1; Agilent Technologies). Probes 
within each probe set were summarized by robust multi-
array analysis (RMA). Signal intensities were quantile-
normalized across all samples to reduce inter-array 
variability. Input data pre-processing was concluded by 
baseline transformation of each probe set to the median of 
all samples. After grouping of samples siGDF-15 versus 
siScrambled, a given transcript had to be expressed above 
background (i.e. fluorescence signal of a given probe set 
was detected within the 20th and 100th percentiles of the 
signal distribution of a given array) in the three biological 
replicates to be further analyzed. Significant differential 
gene expression was determined using unpaired t-tests.
miRNA expression profiling
miRNA expression profiling was done with LNT-
229 and LN-308 cells with a silenced GDF-15 gene or 
control cells as described above. Total RNA was extracted 
from the cells using TRIzol reagent (Life Technologies). 
Biological duplicates were processed from control or 
GDF-15 silenced LNT-229 and LN-308 cells.
Size selection for 21 nt small RNA (sRNA) fraction 
was done from 10 μg total RNA separated on a 12% urea 
PAGE. After gel run, a piece corresponding to 19 to 24 nt 
RNA was excised and RNA was eluted from gel overnight 
by passive diffusion into elution buffer [300 mM NaCl, 2 
mM EDTA] at 25 °C. RNA was precipitated from eluate 
with 75% ethanol overnight and dissolved in water. Small 
RNA cloning from the sRNA fraction was essentially done 
as described before [39] using 75% of the isolated sRNA 
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fraction. Cluster generation, sequencing and FastQ file 
generation were carried out at the sequencing core facility 
Center of Excellence for Fluorescent Bioanalytics KFB 
at the University of Regensburg. Cluster generation was 
done with TruSeq SR Cluster Kit v3 on a cBOT (Illumina, 
San Diego, CA). Sequencing was performed on a HiScan 
SQ (Illumina) using TruSeq SBS v3 in 50 bp single-end 
runs with 10 samples per lane. FastQ files were generated 
by CASAVA 1.8.
Deep sequencing data were processed with in house 
software and annotated against Homo sapiens miRBase 
Version 19 without any allowed mismatches. Only miRNA 
with more than 20 reads per million reads (rpmr) as mean 
value over all samples were included into analysis.
Search tool for the retrieval of interacting Genes/
proteins (STRING) analysis
The interactome of mRNA which are regulated in a 
GDF-15-dependent manner in LNT-229 and LN-308 cells 
was delineated using the STRING 9.1 platform (http://
string-db.org; [40]. Interactions with a confidence score 
of 0.7 or higher were integrated using all available active 
prediction methods.
Statistics
Data are expressed as mean and standard error 
of the mean. The experiments shown were repeated at 
least three times with similar results. Data are shown 
as a representative result. Analysis of significance for 
overall survival probability curves was done using the 
Cochran-Armitage comparison for Pearson’s chi-square 
fit. For analysis of GDF-15 expression levels in the TCGA 
datasets, ANOVA (Kruskal-Wallis test) with Dunn’s 
multiple comparison test was applied. For all other data, 
unpaired, two-tailed Student’s t-test were performed 
(GraphPad Prism 5, La Jolla, CA) (*p < 0.05, **p < 0.01).
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